Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients
Treating Non-small Cell Lung Cancer (NSCLC) Patients with MET exon 14mutations with Savolitinib
Non-small Cell Lung Cancer Metastatic
DRUG: Savolitinib
Objective response rate (ORR) evaluated by the Independent Review Committee (IRC) (RECIST 1.1 criteria), To evaluate the efficacy of Savolitinib in the treatment of locally advanced or metastatic NSCLC patients with MET exon 14 mutations, through study completion, an average of 3 years
Progression-free survival (PFS) (RECIST 1.1 criteria), To evaluate the efficacy of Savolitinib in the treatment of locally advanced or metastatic NSCLC patients with MET exon 14 mutations, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months|incidence of various adverse events (AE), To evaluate the safety and tolerability of Savolitinib in the treatment of locally advanced or metastatic NSCLC patients with MET exon 14 mutations, through study completion, an average of 3 years
This is a single-arm, multi-cohort, multi-center, open-label, phase IIIb clinical study. The objective is to evaluate the efficacy and safety of Savolitinib in the treatment of locally advanced or metastatic NSCLC patients with MET exon 14 mutations. The study involves a Screening Period, a Treatment Period and a Follow-up Period. There are 53 study sites initiated and enrolled 203 advanced or metastatic NSCLC patients with MET exon 14 mutations